Timothy Thompson has joined Proventys as president and CEO of the firm. He formerly served as managing director of business development at Aetna. In addition, Proventys said that Marc Owen, executive vice president of corporate strategy and business development at McKesson, has joined the firm's board of directors.
Â
Â
David Gandara has joined Response Genetics’ board of directors. Gandara is a professor of medicine at the University of California, Davis, School of Medicine and he is director of clinical research and director of the thoracic oncology program at the UC-Davis Cancer Center. He also is a member of the board of directors at the International Association for the Study of Lung Cancer and at the Addario Foundation. He has been a director at the American Society of Clinical Oncology and he serves on professional committees at the National Cancer Institute.
Â
Â
Lynda Merrill joined Qiagen as VP of molecular diagnostics sales for Europe, Middle East, Africa, and Australia at the beginning of May, the company said last week. Merrill, who will be based in the UK, formerly was a VP at Gen-Probe and she served in management roles at Boehringer Mannheim.
Â
Â
Human Genome Sciences last week announced that Kevin McRaith had joined the company as the new vice president of its hepatology division. McRaith was formerly vice president of sales and marketing of Genentech's hematology division, where he led the commercial efforts for the drug Rituxan (rituximab). Before Genenetch, McRaith worked in various positions at Abbott Laboratories for 15 years.